Hurdle using AI to transform diagnostic innovation
Hurdle is using an artificial intelligence-enabled platform to advance diagnostic development and support precision medicine in the healthcare sector.
The company, led by Founder and Chief Executive Officer Tom Stubbs, seeks to address barriers that have historically slowed down the field of diagnostics, such as fragmented systems, challenging regulatory environments and operational inefficiencies. By focusing on AI-driven automation and the integration of multi-modal data, Hurdle aims to accelerate innovation and facilitate the delivery of diagnostic tools in a faster and more resource-efficient manner.
Stubbs, who has a background in epigenetics, molecular and cellular biochemistry, as well as computational biology, has stated that Hurdle is dedicated to building the infrastructure required to transform healthcare by empowering diagnostics companies to scale their solutions efficiently.
According to the company, "The diagnostics industry has long been constrained by fragmented systems, complex regulatory pathways, and operational friction, delaying life-changing innovation. Hurdle is solving these challenges by providing an AI-enabled diagnostics platform that integrates multi-modal data, automated regulatory compliance, leading scientific expertise and flexible lab networks. By standardising key processes, Hurdle empowers diagnostics companies to achieve breakthroughs at a pace previously unattainable, fundamentally shifting the economics of bringing new innovations to market."
Instead of requiring partners to build intricate operational systems from scratch, Hurdle's platform offers integrated solutions that support activities from test validation and regulatory submission through to clinical adoption. The company states that this approach can result in faster test validation and improved patient access, while making it easier to transition diagnostic products from research settings to real-world clinical environments.
Hurdle explained that, "Hurdle's platform offers its partners a seamless solution without the burden of building complex operational systems from the ground up. This allows for faster test validation, improved patient access, and a fluid transition from research to real-world clinical adoption. By standardising diagnostics infrastructure, Hurdle is making innovation scalable, accessible, and more equitable worldwide."
The platform provides a range of end-to-end features, including biomarker discovery, support for clinical validation, regulatory compliance, commercialisation and global deployment. Hurdle has also established partnerships with other healthcare and diagnostics entities, such as Bayer and Eurofins. According to the company, these collaborations highlight a broader demand for a connected and sophisticated diagnostics ecosystem.
The company noted, "Hurdle's AI-enabled platform offers end-to-end capabilities spanning biomarker discovery, clinical validation, regulatory compliance, commercialisation and global deployment. The company's partnerships with industry leaders—including Bayer and Eurofins—demonstrate the growing demand for an integrated, intelligent diagnostics ecosystem. By automating regulatory workflows and leveraging AI-driven insights, Hurdle is enabling biotech, pharma, and healthcare providers to bring cutting-edge diagnostics to patients faster and more efficiently."
As the healthcare sector increasingly moves towards personalised and data-driven approaches, Hurdle regards scalable infrastructure as key to accelerating progress and addressing inefficiencies. The company sees its strategy as broader than traditional laboratory-based diagnostics, focusing on integration of multiple data types and advanced artificial intelligence models.
"As healthcare advances toward a more data-driven and personalised model, scalable AI-enabled infrastructure is critical to unlocking new innovations and removing bottlenecks. Hurdle's role in transforming diagnostics extends beyond traditional lab-based approaches—by integrating multi-modal data and next-generation AI models, the company is driving a new era of precision medicine that will ultimately deliver better health and care for everyone," the company stated.
Hurdle further believes that by tackling longstanding procedural inefficiencies and standardising key parts of the diagnostics value chain, it is playing a pivotal part in the sector's ongoing transformation.
The company said, "By addressing long-standing inefficiencies and standardising the diagnostics pipeline, the company is not just keeping pace with industry change—it is driving it. As precision health continues to evolve, Hurdle's AI-powered platform is poised to unlock unprecedented medical advancements, making breakthrough diagnostics more accessible, scalable, and impactful than ever before."
